TumorPhase 3NCT00472303
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
A Phase 3 study testing Tapentadol Extended Release in people with Tumor and Pain, run by Grünenthal GmbH at 71 sites in 16 countries.
Trial summary
The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo. In addition tapentadol (CG5503) will also be compared to morphine controlled release, also referred to as slow release (SR). Read more about this study
- Who is it for?
- Ages 18 years and older
- What is being tested?
- Tapentadol Extended Release
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 622 participants
- Where
- 71 sitesin 16 countries
- Study dates
- Jul 2007to Jun 2012
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and non-pregnant, non-lactating female subjects.
- Of at least 18 years of age with chronic malignant tumor-related pain with a mean pain intensity (NRS) of 5 points or higher.
- Subjects who are opioid-naïve or pretreated with an equianalgesic dose range equivalent of up to 160 mg oral morphine per day and are dissatisfied with prior treatment.
- Women must be postmenopausal, surgically sterile, or practicing or agree to practice an effective method of birth control throughout the trial.
- Expected course of the disease and the pain that would permit compliance with the trial protocol over the entire trial period.
Who cannot join
- Subjects will be excluded from the study if they have a history of seizure disorder or epilepsy;
- known history and/or presence of cerebral tumor or cerebral metastases.
- history of alcohol or drug abuse;
- uncontrolled hypertension,
- clinical laboratory values reflecting severe renal insufficiency,
- moderate or severe hepatic impairment,
Show all 12Show fewer
- hepatitis B or C, HIV,
- inadequate bone marrow reserve
- currently treated with radiotherapy,
- pain-inducing chemotherapy,
- anti-parkinsonian drugs, neuroleptics, monoamine oxidase inhibitors, serotonin norepinephrine reuptake inhibitor (SNRI) or any other analgesic therapy than investigational medication or rescue medication during the trial.
- selective serotonin reuptake inhibitor (SSRI) treatments are allowed if taken for at least 30 days before the screening period of the study at an unchanged dose.
Trial locations and contacts
71 sites in 16 countries.
71 sites in 16 countries
Czechia7 sites
Site 420005
Brno, 62500
Site 420002
České Budějovice, 37087
Site 420006
Hradec Králové, 50005
Site 420007
Liberec, 46063
Site 420008
Olomouc, 77520
Site 420001
Pilsen, 30460
Site 420004
Prague, 18181
Germany7 sites
Site 049009
Berlin, 12627
Site 049012
Cologne, 50996
Site 049014
Essen, 45122
Site 049007
Löwenstein, 74245
Site 049020
Potsdam, 14467
Site 049006
Waldkirch, 79183
Site 049002
Wiesbaden, 65185
Hungary7 sites
Site 036001
Debrecen, 4043
Site 036005
Komárom, 2900
Site 036003
Mátraháza, 3233
Site 036002
Nyíregyháza, 4412
Site 036006
Székesfehérvár, 8000
Site 036009
Székesfehérvár, 8000
Site 036010
Szekszárd, 7100
Romania7 sites
Site 040006
Brasov, 500074
Site 040002
Bucharest, 022328
Site 040003
Bucharest, 022328
Site 040004
Bucharest, 022328
Site 040005
Cluj-Napoca, 400015
Site 040001
Iași, 700106
Site 040007
Timișoara, 300239
Bulgaria6 sites
Site 359013
Gabrovo, 5300
Site 359011
Pleven, 5800
Site 359014
Plovdiv, 4004
Site 359004
Shumen, 9700
Site 359008
Sofia, 1784
Site 359012
Varna, 9003
Croatia6 sites
Site 385007
Osijek, 31000
Site 385001
Slavonski Brod, 35000
Site 385004
Varaždin, 42000
Site 385006
Zabok, 49210
Site 385002
Zagreb, 10000
Site 385003
Zagreb, 10000
Spain6 sites
Site 034009
Barcelona, 08208
Site 034005
Barcelona, 08221
Site 034006
Mahón, 07703
Site 034012
Pamplona, 31008
Site 034004
Seville, 1013
Site 034002
Valencia, 46014
Russia5 sites
Site 007010
Arkhangelsk, 163045
Site 007003
Moscow, 125284
Site 007007
Nizhny Novgorod, 603140
Site 007012
Vladikavkaz, 362007
Site 007005
Yaroslavl, 150054
Serbia5 sites
Site 381003
Belgrade, 11000
Site 381004
Belgrade, 11000
Site 381005
Belgrade, 11000
Site 381001
Kamenitz, 21204
Site 381002
Niš, 18000
Austria4 sites
Site 043004
Klagenfurt, 9020
Site 043002
Vienna, 1020
Site 043001
Vienna, 1090
Site 043005
Vienna, 1100
Poland4 sites
Site 048004
Bydgoszcz, 85796
Site 048005
Gdansk, 80286
Site 048007
Poznan, 60355
Site 048001
Warsaw, 02781
About this study
Official title: A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) PR* in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain
The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo. In addition tapentadol (CG5503) will also be compared to morphine controlled release, also referred to as slow release (SR).
*Tapentadol prolonged-release (PR) is the term used in the European Union and is referred to as extended release (ER) in the United States.
Read the detailed description
Normally chronic tumor related pain is controlled when participants receive repeated doses of opioid analgesics. However, opioid therapy is commonly associated with side effects such as nausea, vomiting, sedation, constipation, addiction, tolerance, and respiratory depression. Tapentadol (CG5503), a newly synthesized drug with an prolonged release (PR) formulation, also acts as a centrally acting pain reliever but has 2 mechanisms of action. The aim of this trial is to investigate the effectiveness (level of pain control) and safety (side effects) of tapentadol (CG5503) PR compared with no drug (placebo) and corresponding dose of morphine (an opioid commonly used to treat tumor related pain). This trial is a randomized, double-blind (neither investigator nor patient will know which treatment was received), active- and placebo-controlled, parallel-group, randomized withdrawal design, multicenter trial.
The trial includes a 2 week titration phase starting with either 40 mg morphine (PR) bid (bid = twice daily dosing, one dose in the morning and one dose in the evening) or 100 mg tapentadol (CG5503) PR bid. Based on effectiveness and side effects subjects can up-titrate in steps of 50 mg tapentadol (CG5503 PR) to a maximal dose of 250 mg tapentadol (CG5503) PR bid or 100 mg morphine PR bid. If participants meet the stabilisation criteria at the end of the titration phase they will be re-randomized to either placebo or active treatment and will continue 4 weeks at the last dose level in the maintenance phase. Only participants on tapentadol in the titration phase will be re-randomized to either matching placebo or to tapentadol. To maintain the blinding nature of the trial participants in the morphine arm during the titration phase will also be re-randomized however they will all remain on morphine controlled release in the maintenance phase. Placebo to match tapentadol tablets, as well as placebo to match morphine capsules, will be used to mask the treatment allocation.
Participants will be issued with an electronic diary (eDiary) to capture Numeric Rating Scale (NRS) pain intensities.
Assessments of pain relief include the pain intensity numeric rating scale (NRS) and patient global impression of change (PGIC). Safety evaluations include monitoring of adverse events, physical examinations, clinical laboratory tests and electrocardiograms. Venous blood samples will be collected for the determination of serum concentrations of tapentadol (CG5503).
- Being tested
- Tapentadol Extended Release, Matching Placebo after Tapentadol in the Titration Phase., Morphine Sulphate Controlled Release
- Keywords
- Opioid, Central acting analgesic, CG5503 PR, Tumor related pain, Cancer related pain, Morphine, Pain assessment, Placebo
- Medical subject headings
- Neoplasms, Pain, Cancer Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tapentadol Extended ReleaseDrug
Also called Palexia, Nucynta, Yantil
Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.
Matching Placebo after Tapentadol in the Titration Phase.Drug
Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.
Morphine Sulphate Controlled ReleaseDrug
Also called MST® CONTINUS®
Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
| Study group | Role | What they receive |
|---|---|---|
| Matching Placebo after Tapentadol in Titration Phase | Placebo comparator | Oral Tapentadol 100 mg to 250 mg twice daily. Participants randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off the tapentadol dose they had received in the Titration Phase. From the 4th day (Day 18) all participants received matching placebo in the maintenance (i.e. randomized withdrawal) phase. Receives: Drug: Tapentadol Extended Release; Drug: Matching Placebo after Tapentadol in the Titration Phase. |
| Morphine Controlled Release | Active comparator | Oral Morphine 40 mg to 100 mg twice daily. Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Maintenance phase: continuing on dose level established in titration phase. Receives: Drug: Morphine Sulphate Controlled Release |
| Tapentadol Prolonged Release | Experimental | Oral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Receives: Drug: Tapentadol Extended Release |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants Scored as Responder in Maintenance Phase.
A "responder" is a participant in the study that:
- completed 28 days of the maintenance phase
- had a numeric rating scale score below 5 on the 11 point scale (where 0 indicates no pain and 10 indicates worst possible pain. This twice daily current pain score was averaged over Day 18 to Day 43.
- did not use more than 20 mg of rescue medication per day on average in the 28 day maintenance period (from Day 18 to Day 43).
A participant that met all 3 of the above-mentioned criteria is counted as a responder, in other words the participant benefited from the assigned drug treatment. A participant that failed to meet only 1 of the 3 criteria is not counted as a responder.
Measured: Day 18 through Day 43 (End of Maintenance Phase)
Secondary outcomes (22)
Average Daily Pain Intensity Scores, Averaged Per Week by Treatment, During the Titration Phase in the Tapentadol Treatment Arm.
Participants were asked to record their "average pain over the last 24 hours" pain intensity each evening. Average pain scores are the averages of all scores recorded during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".
Measured: Day 1 through Day 14 (End of Titration Phase)
Average Daily Pain Intensity Scores, Averaged Per Week by Treatment, During the Titration Phase in the Morphine Treatment Arm.
Participants were asked to record their "average pain over the last 24 hours" pain intensity each evening. Average pain scores are the averages of all scores recorded during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".
Measured: Day 1 through Day 14 (End of Titration Phase)
Average Daily Pain Intensity Scores, Averaged Per Week by Treatment, During the Maintenance Phase.
Participants were asked to record their "average pain over the last 24 hours" pain intensity each evening. Average pain scores are the averages of all scores recorded during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".
Measured: Day 18 through Day 43 (End of Maintenance Phase)
Current Pain Intensity Scores, Averaged Per Week, During the Titration Phase in the Tapentadol Arm.
Participants were asked to record their current pain intensity in the morning and evening. Average pain scores are the averages of all scores recorded during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".
Measured: Day 1 through Day 14 (End of Titration Phase)
Current Pain Intensity Scores, Averaged Per Week, During the Titration Phase in the Morphine Arm.
Participants were asked to record their current pain intensity in the morning and evening. Average pain scores are the averages of all scores recorded during the during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".
Measured: Day 1 through Day 14 (End of Titration Phase)
Current Pain Intensity Scores, Averaged Per Week by Treatment, During the Maintenance Phase.
Participants were asked to record their current pain intensity in the morning and evening. Average pain scores are the averages of all scores recorded during the 3 days prior to re-randomization or during each week. The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".
Measured: Day 15 through Day 43 (End of Maintenance Phase)
Use of Rescue Medication in the Titration Phase.
The number of participants using rescue medication morphine sulfate immediate release 10 mg tablets in the titration phase were counted. This data was captured in an electronic diary.
During the trial, morphine immediate release 10 mg was allowed as required without a maximum dose defined. However, participants were only re-randomized if their mean consumption of rescue medication was less or equal to 2 doses (20 mg) per day during the last 3 days of the titration phase).
Measured: Day 1 through Day 14 (End of Titration Phase)
Number of Participants Using Immediate Release Morphine Rescue Medication in the Maintenance Phase
Participants were issued morphine 10 mg immediate release medication. The number of participants using rescue medication morphine sulfate immediate release 10 mg tablets in the maintenance phase were counted. This use of morphine immediate release was captured in each participant's electronic diary.
Measured: Day 15 through Day 43 (End of Maintenance Phase)
The Average Mean Total Daily Dose of Rescue Medication.
Mean total daily dose of rescue medication morphine sulphate immediate release tablets in milligrams per day (mg/day).
Measured: Day 1 (Start of Titration Phase) through Day 43 (End of Maintenance Phase)
Changes in the Short Form 36® Health Survey (SF-36®) During the Titration Phase.
The Short Form 36 (SF-36) includes several brief questions on 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. Low scores on the Physical Component Summary measure indicate limitations in physical functioning, e.g. a high degree of bodily pain and physical limitations etc. For the Mental Component Summary measure, a low score is indicative of frequent psychological distress, social and role disability due to emotional problems etc. The theoretical range for the physical component score is 12.3279 to 59.6503. The theoretical range for the mental component score is 13.5313 to 59.6503. Positive values for changes in the component scores indicate an improvement.
Measured: Day 1 (Start of Titration); Day 14 (End of Titration Phase)
Changes in the Short Form 36® Health Survey (SF-36®) During the Maintenance Phase.
The Short Form 36 (SF-36) includes several brief questions on 8 aspects, (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health) that a participant was asked to score over the last week. Low scores on the Physical Component Summary measure indicate limitations in physical functioning, e.g. a high degree of bodily pain and physical limitations etc. For the Mental Component Summary measure, a low score is indicative of frequent psychological distress, social and role disability due to emotional problems etc. The theoretical range for the physical component score is 12.3279 to 59.6503. The theoretical range for the mental component score is 13.5313 to 59.6503. Positive values for changes in the component scores indicate an improvement.
Measured: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)
Change in the EuroQoL (EQ-5D) Health Status Index (United Kingdom Time Trade-off Value Set) Change From Start of Titration to Endpoint Titration.
The participant scores the EuroQol-5D. The EuroQoL-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1 = no problems, 2 = some problems, 3 = extreme problems).
The responses to the five EQ-5D dimensions are scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. A positive change in the mean indicates that during this phase the health status improved. A positive change indicates an improvement in health. The minimal important difference is 0.074 (range -0.011 to 0.140).
Measured: Day 1 (Start of Titration); Day 14 (End of Titration Phase)
Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) Titration Phase.
EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate better health. The values indicated represent the change from Day 1, a positive value indicates an improvement since the start of treatment.
Measured: Day 1 (Start of Titration); Day 14 (End of Titration Phase)
Change in the EuroQoL (EQ-5D) Health Status Index (United Kingdom Time Trade-off Value Set) Over Time in the Maintenance Phase for Tapentadol and the Placebo Randomized Withdrawal Treatment Arms.
The participant scores the EuroQol-5D. The EuroQoL-5D is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1 = no problems, 2 = some problems, 3 = extreme problems).
The responses to the five EQ-5D dimensions are scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. A negative change in the mean indicates a worsening in health status since the beginning of the maintenance phase. A positive change indicates an improvement in health. The minimal important difference in the Health Status Index is 0.074 (range -0.011 to 0.140).
Measured: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)
Changes in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) Maintenance Phase.
EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The values indicated represent the change from Day 15, a negative mean value indicates a worsening of health-related quality of life since the start of the maintenance phase.
Measured: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)
Patient Global Impression of Change
In the Patient Global Impression of Change (PGIC) the participant is asked "Since I began study treatment, my overall status is". The participant is asked to circle one of seven categories. Scores range from very much improved to very much worse. The question was asked at the end of the maintenance phase with reference to the start of the maintenance phase where the participant continued at the dose that was effective at the end of the Titration Phase.
Measured: Day 43 (End of Maintenance Phase)
Quality of Sleep (Sleep Questionnaire) in the Titration Phase.
Participants were asked the following question: "Please rate the overall quality of your sleep last night?" The quality of sleep from the start of the titration phase to the end of the titration phase was measured. The participant could choose one of the following options: Excellent, good, fair and poor.
Measured: Day 1 (Start of Titration); Day 14 (end of Titration Phase)
Quality of Sleep (Sleep Questionnaire) During the Maintenance Phase of the Trial.
Participants were asked the following question: "Please rate the overall quality of your sleep last night?" The quality of sleep from the start of maintenance to the completion of treatment is reported. The participant could choose one of the following options: Excellent, good, fair and poor.
Measured: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)
Clinical Opioid Withdrawal Scale (COWS) at the End of the Titration Phase.
This instrument was developed by the National Institute on Drug Abuse. The physical components of withdrawal are primarily evaluated and based on questions and clinical observations. The possible opioid withdrawal effects are assessed using the Clinical Opioid Withdrawal Score (COWS). The COWS is a clinician rated 11-item scale that primarily evaluates the physical components of opioid withdrawal and is based on questions and clinical observations. Responses are rated on a Likert-type scale ranging from 0 to 4 or 5 depending on the item. The total COWS score is the sum of all individual items.
The following withdrawal categories are based on the total COWS score:
- None: total score below 5;
- Mild: total score from 5 to 12;
- Moderate: total score 13 to 24;
- Moderately Severe: total score 25 to 36;
- Severe: total score above 36. The investigator completes the COWS after participants discontinued trial medication 2 to less than 5 days after last intake of trial medication.
Measured: Day 14 (End of Titration Phase)
Clinical Opioid Withdrawal Score (COWS) at the End of the Maintenance Phase.
This instrument was developed by the National Institute on Drug Abuse. The physical components of withdrawal are primarily evaluated and based on questions and clinical observations. The possible opioid withdrawal effects are assessed using the Clinical Opioid Withdrawal Score (COWS). The COWS is a clinician rated 11-item scale that primarily evaluates the physical components of opioid withdrawal and is based on questions and clinical observations. Responses are rated on a Likert-type scale ranging from 0 to 4 or 5 depending on the item. The total COWS score is the sum of all individual items.
The following withdrawal categories are based on the total COWS score:
- None: total score below 5;
- Mild: total score from 5 to 12;
- Moderate: total score 13 to 24;
- Moderately Severe: total score 25 to 36;
- Severe: total score above 36. The investigator completes the COWS after participants discontinued trial medication 2 to less than 5 days after last intake of trial medication.
Measured: Day 43 (End of Maintenance Phase)
Change in the Patient Assessment of Constipation Symptoms (PAC-SYM) During the Titration Phase
The Constipation Assessment (PAC-SYM) is a 12-item self-report questionnaire that assesses the severity of symptoms of constipation. Participants are asked "How severe have each of these symptoms been in the last two weeks?" e.g. "Pain in your stomach". There are 3 subscales: 4 questions on Abdominal symptoms, 3 questions on rectal symptoms and 5 questions on stool symptoms. Responses are rated on a 5-point Likert Scale ranging from 0 (absence of symptom) to 4 (very severe symptoms). The changes in overall mean and in each of the mean sub-scores vary theoretically from -4 to +4 (where a change of +4 would indicate a change from not present to very severe symptom). If the changes in the overall or subscale mean scores are positive then there is a worsening in symptoms associated with constipation from the start to the end of the titration phase.
Measured: Day 1 (Start of Titration); Day 14 (End of Titration Phase)
Change in the Patient Assessment of Constipation Symptoms (PAC-SYM) During the Maintenance Phase
The Constipation Assessment (PAC-SYM) is a 12-item self-report questionnaire that assesses the severity of symptoms of constipation. Participants are asked "How severe have each of these symptoms been in the last two weeks?" e.g. "Pain in your stomach". There are 3 subscales: 4 questions on Abdominal symptoms, 3 questions on rectal symptoms and 5 questions on stool symptoms. Responses are rated on a 5-point Likert Scale ranging from 0 (absence of symptom) to 4 (very severe symptoms). The changes in overall mean and in each of the mean sub-scores vary theoretically from -4 to +4 (where a change of +4 would indicate a change from not present to very severe symptom). If the changes in the overall or subscale mean scores are positive then there is a worsening in symptoms associated with constipation from the start to the end of the maintenance phase. A negative mean change indicates an improvement.
Measured: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2007 (estimated)
- Study startJul 2007
- Primary completionJun 2012
- Study completionJun 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for TumorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 622 participants (actual)
Sponsor and investigators
- Lead sponsor
- Grünenthal GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Responsible party
- Sponsor
- Investigators
- Hans Georg Kress, Dr., Principal investigator, Clinic of Anaesthesiology and Pain Management, AKH Vienna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00472303
- Sponsor's protocol ID
- 761101
- Other IDs
- 2006-004997-28, KF5503/15
- Status last verified
- Oct 2019
- First submitted
- 10 May 2007
- Last updated
- 4 Nov 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, Dogan C, Etropolski MS, Eerdekens M. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician. 2014 Jul-Aug;17(4):329-43.
PubMed 25054392Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Dogan C, Etropolski M, Eerdekens M. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. Eur J Pain. 2016 Oct;20(9):1513-8. doi: 10.1002/ejp.875. Epub 2016 Apr 7.
PubMed 27062079
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) PR* in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain
- ClinicalTrials.gov ID
- NCT00472303
- Acronym / sponsor ID
- 761101
- Keywords
- Opioid, Central acting analgesic, CG5503 PR, Tumor related pain, Cancer related pain, Morphine, Pain assessment, Placebo
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 622 participants (actual)
- Lead sponsor
- Grünenthal GmbHIndustry (pharma, biotech, devices)
- Collaborators
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Study start
- Jul 2007
- Primary completion
- Jun 2012 (actual)
- Study completion
- Jun 2012 (actual)
- First posted
- 11 May 2007 (estimated)
- Results
- Posted 7 May 2014
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo. In addition tapentadol (CG5503) will also be compared to morphine controlled release, also referred to as slow release (SR).
*Tapentadol prolonged-release (PR) is the term used in the European Union and is referred to as extended release (ER) in the United States.
Detailed description
Normally chronic tumor related pain is controlled when participants receive repeated doses of opioid analgesics. However, opioid therapy is commonly associated with side effects such as nausea, vomiting, sedation, constipation, addiction, tolerance, and respiratory depression. Tapentadol (CG5503), a newly synthesized drug with an prolonged release (PR) formulation, also acts as a centrally acting pain reliever but has 2 mechanisms of action. The aim of this trial is to investigate the effectiveness (level of pain control) and safety (side effects) of tapentadol (CG5503) PR compared with no drug (placebo) and corresponding dose of morphine (an opioid commonly used to treat tumor related pain). This trial is a randomized, double-blind (neither investigator nor patient will know which treatment was received), active- and placebo-controlled, parallel-group, randomized withdrawal design, multicenter trial.
The trial includes a 2 week titration phase starting with either 40 mg morphine (PR) bid (bid = twice daily dosing, one dose in the morning and one dose in the evening) or 100 mg tapentadol (CG5503) PR bid. Based on effectiveness and side effects subjects can up-titrate in steps of 50 mg tapentadol (CG5503 PR) to a maximal dose of 250 mg tapentadol (CG5503) PR bid or 100 mg morphine PR bid. If participants meet the stabilisation criteria at the end of the titration phase they will be re-randomized to either placebo or active treatment and will continue 4 weeks at the last dose level in the maintenance phase. Only participants on tapentadol in the titration phase will be re-randomized to either matching placebo or to tapentadol. To maintain the blinding nature of the trial participants in the morphine arm during the titration phase will also be re-randomized however they will all remain on morphine controlled release in the maintenance phase. Placebo to match tapentadol tablets, as well as placebo to match morphine capsules, will be used to mask the treatment allocation.
Participants will be issued with an electronic diary (eDiary) to capture Numeric Rating Scale (NRS) pain intensities.
Assessments of pain relief include the pain intensity numeric rating scale (NRS) and patient global impression of change (PGIC). Safety evaluations include monitoring of adverse events, physical examinations, clinical laboratory tests and electrocardiograms. Venous blood samples will be collected for the determination of serum concentrations of tapentadol (CG5503).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Matching Placebo after Tapentadol in Titration Phase | Placebo comparator | Drug: Tapentadol Extended Release, Drug: Matching Placebo after Tapentadol in the Titration Phase.Oral Tapentadol 100 mg to 250 mg twice daily. Participants randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off the tapentadol dose they had received in the Titration Phase. From the 4th day (Day 18) all participants received matching placebo in the maintenance (i.e. randomized withdrawal) phase. |
| Morphine Controlled Release | Active comparator | Drug: Morphine Sulphate Controlled ReleaseOral Morphine 40 mg to 100 mg twice daily. Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Maintenance phase: continuing on dose level established in titration phase. |
| Tapentadol Prolonged Release | Experimental | Drug: Tapentadol Extended ReleaseOral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male and non-pregnant, non-lactating female subjects.
- Of at least 18 years of age with chronic malignant tumor-related pain with a mean pain intensity (NRS) of 5 points or higher.
- Subjects who are opioid-naïve or pretreated with an equianalgesic dose range equivalent of up to 160 mg oral morphine per day and are dissatisfied with prior treatment.
- Women must be postmenopausal, surgically sterile, or practicing or agree to practice an effective method of birth control throughout the trial.
- Expected course of the disease and the pain that would permit compliance with the trial protocol over the entire trial period.
Key exclusion criteria (12 listed)
- Subjects will be excluded from the study if they have a history of seizure disorder or epilepsy;
- known history and/or presence of cerebral tumor or cerebral metastases.
- history of alcohol or drug abuse;
- uncontrolled hypertension,
- clinical laboratory values reflecting severe renal insufficiency,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tapentadol Extended ReleaseAlso: Palexia, Nucynta, YantilTablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg. | Drug | Matching Placebo after Tapentadol in Titration Phase, Tapentadol Prolonged Release |
| Matching Placebo after Tapentadol in the Titration Phase.Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase. | Drug | Matching Placebo after Tapentadol in Titration Phase |
| Morphine Sulphate Controlled ReleaseAlso: MST® CONTINUS®Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase. | Drug | Morphine Controlled Release |
Primary outcome
Number of Participants Scored as Responder in Maintenance Phase.
Time frame: Day 18 through Day 43 (End of Maintenance Phase)
A "responder" is a participant in the study that: 1. completed 28 days of the maintenance phase 2. had a numeric rating scale score below 5 on the 11 point scale (where 0 indicates no pain and 10 indicates worst possible pain. This twice daily current pain score was averaged over Day 18 to Day 43. 3. did not use more than 20 mg of rescue medication per day on average in the 28 day maintenance period (from Day 18 to Day 43). A participant that met all 3 of the above-mentioned criteria is counted as a responder, in other words the participant benefited from the assigned drug treatment. A participant that failed to meet only 1 of the 3 criteria is not counted as a responder.
22 secondary outcomes
Average Daily Pain Intensity Scores, Averaged Per Week by Treatment, During the Titration Phase in the Tapentadol Treatment Arm.
Time frame: Day 1 through Day 14 (End of Titration Phase)
Average Daily Pain Intensity Scores, Averaged Per Week by Treatment, During the Titration Phase in the Morphine Treatment Arm.
Time frame: Day 1 through Day 14 (End of Titration Phase)
Average Daily Pain Intensity Scores, Averaged Per Week by Treatment, During the Maintenance Phase.
Time frame: Day 18 through Day 43 (End of Maintenance Phase)
Current Pain Intensity Scores, Averaged Per Week, During the Titration Phase in the Tapentadol Arm.
Time frame: Day 1 through Day 14 (End of Titration Phase)
Current Pain Intensity Scores, Averaged Per Week, During the Titration Phase in the Morphine Arm.
Time frame: Day 1 through Day 14 (End of Titration Phase)
Current Pain Intensity Scores, Averaged Per Week by Treatment, During the Maintenance Phase.
Time frame: Day 15 through Day 43 (End of Maintenance Phase)
Use of Rescue Medication in the Titration Phase.
Time frame: Day 1 through Day 14 (End of Titration Phase)
Number of Participants Using Immediate Release Morphine Rescue Medication in the Maintenance Phase
Time frame: Day 15 through Day 43 (End of Maintenance Phase)
The Average Mean Total Daily Dose of Rescue Medication.
Time frame: Day 1 (Start of Titration Phase) through Day 43 (End of Maintenance Phase)
Changes in the Short Form 36® Health Survey (SF-36®) During the Titration Phase.
Time frame: Day 1 (Start of Titration); Day 14 (End of Titration Phase)
Changes in the Short Form 36® Health Survey (SF-36®) During the Maintenance Phase.
Time frame: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)
Change in the EuroQoL (EQ-5D) Health Status Index (United Kingdom Time Trade-off Value Set) Change From Start of Titration to Endpoint Titration.
Time frame: Day 1 (Start of Titration); Day 14 (End of Titration Phase)
Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) Titration Phase.
Time frame: Day 1 (Start of Titration); Day 14 (End of Titration Phase)
Change in the EuroQoL (EQ-5D) Health Status Index (United Kingdom Time Trade-off Value Set) Over Time in the Maintenance Phase for Tapentadol and the Placebo Randomized Withdrawal Treatment Arms.
Time frame: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)
Changes in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS) Maintenance Phase.
Time frame: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)
Patient Global Impression of Change
Time frame: Day 43 (End of Maintenance Phase)
Quality of Sleep (Sleep Questionnaire) in the Titration Phase.
Time frame: Day 1 (Start of Titration); Day 14 (end of Titration Phase)
Quality of Sleep (Sleep Questionnaire) During the Maintenance Phase of the Trial.
Time frame: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)
Clinical Opioid Withdrawal Scale (COWS) at the End of the Titration Phase.
Time frame: Day 14 (End of Titration Phase)
Clinical Opioid Withdrawal Score (COWS) at the End of the Maintenance Phase.
Time frame: Day 43 (End of Maintenance Phase)
Change in the Patient Assessment of Constipation Symptoms (PAC-SYM) During the Titration Phase
Time frame: Day 1 (Start of Titration); Day 14 (End of Titration Phase)
Change in the Patient Assessment of Constipation Symptoms (PAC-SYM) During the Maintenance Phase
Time frame: Day 15 (Start of Maintenance); Day 43 (End of Maintenance Phase)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 25054392Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, Dogan C, Etropolski MS, Eerdekens M. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician. 2014 Jul-Aug;17(4):329-43.
- Results publication: PubMed 27062079Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Dogan C, Etropolski M, Eerdekens M. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. Eur J Pain. 2016 Oct;20(9):1513-8. doi: 10.1002/ejp.875. Epub 2016 Apr 7.
Related trials for Tumor
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hans Georg Kress, Dr. principal investigator
Clinic of Anaesthesiology and Pain Management, AKH Vienna
71 sites in 16 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Tapentadol Extended Release in people with Tumor and Pain, run by Grünenthal GmbH at 71 sites in 16 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 71 sites in Czechia, Germany, Hungary, Romania, Bulgaria and 11 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 May 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants Scored as Responder in Maintenance Phase. (time frame: Day 18 through Day 43 (End of Maintenance Phase)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00472303, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2019.